我TMD工具箱里的第一种药物

David Dean
{"title":"我TMD工具箱里的第一种药物","authors":"David Dean","doi":"10.1080/08869634.2020.1691707","DOIUrl":null,"url":null,"abstract":"Temporomandibular disorders (TMDs) are a highly prevalent group of interrelated conditions affecting the temporomandibular joints, muscles of mastication, and intra-articular structures [1]. Understanding the pathophysiology of TMD and the nuances between subtypes is paramount in management, particularly when incorporating medications into care. Dentists expertly employ local anesthetics, analgesics, sedatives, and antibiotics in daily practice, but many feel less confident prescribing medications when treating TMD. This editorial will highlight medications I have found to be particularly useful, with an eye on optimal medication selection. In contrast to many musculoskeletal pain conditions, the great majority of individuals with TMD improve over time without invasive therapy [2–5]. While the effectiveness of conservative therapy is encouraging, this also suggests the potential role that medications may play to improve quality of life when symptoms are present. Unfortunately, pharmacotherapy in TMD has not been rigorously studied in large randomized trials [6,7]. When scientific literature is less than ideal, we are left to make the best choices for our patients with the data available. I encourage each of you to explore the data and compare my experiences with those in your practice to determine if judicious use of medication could be beneficial as part of a comprehensive care protocol. In my practice, I have found three classes to be particularly useful: non-steroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, and tricyclic antidepressants. Understanding the indications for each, and the characteristics of drugs in each class, allows for application in a variety of circumstances. The first consideration when prescribing is also the simplest: Why prescribe at all? Before “reaching for the prescription pad,” one must be able to clearly articulate the precise goals of therapy. What am I trying to accomplish with this drug? Are alternative therapies available? Would pharmacotherapy help to improve function or quality of life in a condition that cannot be cured? Answers vary in each individual circumstance. Non-steroidal anti-inflammatory drugs are useful in treating many dental and orofacial conditions, due to their analgesic and anti-inflammatory properties. In TMD, they are the drugs of choice in treating acute (e.g., capsulitis) and chronic (e.g., degenerative joint disease) inflammatory conditions within the joint [6,8,9]. NSAIDs can provide acute pain relief in myalgia but are less effective in treating chronic myofascial pain, likely because most muscular pain is not caused by inflammation [10]. All NSAIDs inhibit cyclooxygenase 2 (COX-2), resulting in decreased synthesis of prostaglandin E2, a key mediator in inflammation and pain sensitization [11]. Unfortunately, most also block structurally similar COX-1, which negatively affects platelet aggregation, kidney function, and protection of gastrointestinal mucosa [12,13]. NSAIDs are cautioned in patients taking antiplatelet and anticoagulant drugs, due to increased bleeding risk, especially in the GI tract. Risk factors for GI bleeding include past history of GI bleeding, gastric and duodenal ulcers, H. pylori infection, alcohol and tobacco use, and age over 65 [13]. Short-term use is unlikely to produce GI symptoms de novo, with meta-analysis reporting 2–3 months of continuous therapy to induce symptoms when non-indomethacin NSAIDs are taken at recommended doses [14]. Ibuprofen is considered first-line therapy in temporomandibular joint (TMJ) arthralgia [15]. It is effective, inexpensive, and widely available [8,15,16]. The analgesic effect compares favorably to other NSAIDs [17]; however, higher doses (600 mg QID) are required to produce anti-inflammatory effects comparable to more potent NSAIDs [18,19]. The anti-inflammatory effect is important to consider, given the observation that pain relief in TMJ arthralgia may be due to decreased inflammation rather than direct pain relief [20,21]. Many patients struggle to be compliant with fourtimes-daily dosing. Use of a once-daily medication can help alleviate this issue. In healthy individuals, I often begin with piroxicam 10 mg daily for 10–14 days. While it is an excellent anti-inflammatory, piroxicam has greater potential for GI side effects than many NSAIDs [16]. CRANIO®: THE JOURNAL OF CRANIOMANDIBULAR & SLEEP PRACTICE 2020, VOL. 38, NO. 1, 1–4 https://doi.org/10.1080/08869634.2020.1691707","PeriodicalId":162405,"journal":{"name":"CRANIO®","volume":"2 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"The first medications in my TMD toolbox\",\"authors\":\"David Dean\",\"doi\":\"10.1080/08869634.2020.1691707\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Temporomandibular disorders (TMDs) are a highly prevalent group of interrelated conditions affecting the temporomandibular joints, muscles of mastication, and intra-articular structures [1]. Understanding the pathophysiology of TMD and the nuances between subtypes is paramount in management, particularly when incorporating medications into care. Dentists expertly employ local anesthetics, analgesics, sedatives, and antibiotics in daily practice, but many feel less confident prescribing medications when treating TMD. This editorial will highlight medications I have found to be particularly useful, with an eye on optimal medication selection. In contrast to many musculoskeletal pain conditions, the great majority of individuals with TMD improve over time without invasive therapy [2–5]. While the effectiveness of conservative therapy is encouraging, this also suggests the potential role that medications may play to improve quality of life when symptoms are present. Unfortunately, pharmacotherapy in TMD has not been rigorously studied in large randomized trials [6,7]. When scientific literature is less than ideal, we are left to make the best choices for our patients with the data available. I encourage each of you to explore the data and compare my experiences with those in your practice to determine if judicious use of medication could be beneficial as part of a comprehensive care protocol. In my practice, I have found three classes to be particularly useful: non-steroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, and tricyclic antidepressants. Understanding the indications for each, and the characteristics of drugs in each class, allows for application in a variety of circumstances. The first consideration when prescribing is also the simplest: Why prescribe at all? Before “reaching for the prescription pad,” one must be able to clearly articulate the precise goals of therapy. What am I trying to accomplish with this drug? Are alternative therapies available? Would pharmacotherapy help to improve function or quality of life in a condition that cannot be cured? Answers vary in each individual circumstance. Non-steroidal anti-inflammatory drugs are useful in treating many dental and orofacial conditions, due to their analgesic and anti-inflammatory properties. In TMD, they are the drugs of choice in treating acute (e.g., capsulitis) and chronic (e.g., degenerative joint disease) inflammatory conditions within the joint [6,8,9]. NSAIDs can provide acute pain relief in myalgia but are less effective in treating chronic myofascial pain, likely because most muscular pain is not caused by inflammation [10]. All NSAIDs inhibit cyclooxygenase 2 (COX-2), resulting in decreased synthesis of prostaglandin E2, a key mediator in inflammation and pain sensitization [11]. Unfortunately, most also block structurally similar COX-1, which negatively affects platelet aggregation, kidney function, and protection of gastrointestinal mucosa [12,13]. NSAIDs are cautioned in patients taking antiplatelet and anticoagulant drugs, due to increased bleeding risk, especially in the GI tract. Risk factors for GI bleeding include past history of GI bleeding, gastric and duodenal ulcers, H. pylori infection, alcohol and tobacco use, and age over 65 [13]. Short-term use is unlikely to produce GI symptoms de novo, with meta-analysis reporting 2–3 months of continuous therapy to induce symptoms when non-indomethacin NSAIDs are taken at recommended doses [14]. Ibuprofen is considered first-line therapy in temporomandibular joint (TMJ) arthralgia [15]. It is effective, inexpensive, and widely available [8,15,16]. The analgesic effect compares favorably to other NSAIDs [17]; however, higher doses (600 mg QID) are required to produce anti-inflammatory effects comparable to more potent NSAIDs [18,19]. The anti-inflammatory effect is important to consider, given the observation that pain relief in TMJ arthralgia may be due to decreased inflammation rather than direct pain relief [20,21]. Many patients struggle to be compliant with fourtimes-daily dosing. Use of a once-daily medication can help alleviate this issue. In healthy individuals, I often begin with piroxicam 10 mg daily for 10–14 days. While it is an excellent anti-inflammatory, piroxicam has greater potential for GI side effects than many NSAIDs [16]. CRANIO®: THE JOURNAL OF CRANIOMANDIBULAR & SLEEP PRACTICE 2020, VOL. 38, NO. 1, 1–4 https://doi.org/10.1080/08869634.2020.1691707\",\"PeriodicalId\":162405,\"journal\":{\"name\":\"CRANIO®\",\"volume\":\"2 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CRANIO®\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/08869634.2020.1691707\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CRANIO®","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/08869634.2020.1691707","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

颞下颌疾病(Temporomandibular disorders, TMDs)是一组非常普遍的相互关联的疾病,影响颞下颌关节、咀嚼肌肉和关节内结构[1]。了解TMD的病理生理学和亚型之间的细微差别在管理中至关重要,特别是在将药物纳入护理时。牙医在日常实践中熟练地使用局部麻醉剂、镇痛药、镇静剂和抗生素,但许多人在治疗TMD时对开药缺乏信心。这篇社论将重点介绍我发现特别有用的药物,并着眼于最佳药物选择。与许多肌肉骨骼疼痛病症相反,绝大多数TMD患者无需侵入性治疗即可随着时间的推移而改善[2-5]。虽然保守疗法的效果令人鼓舞,但这也表明,当出现症状时,药物可能在改善生活质量方面发挥潜在作用。不幸的是,TMD的药物治疗尚未在大型随机试验中得到严格研究[6,7]。当科学文献不够理想时,我们只能根据现有的数据为病人做出最好的选择。我鼓励你们每个人都去探索这些数据,并将我的经验与你们的实践进行比较,以确定作为综合护理方案的一部分,明智地使用药物是否有益。在我的实践中,我发现有三种药物特别有用:非甾体抗炎药(NSAIDs)、肌肉松弛剂和三环抗抑郁药。了解每种药物的适应症和每一类药物的特点,可以在各种情况下应用。开处方的第一个考虑也是最简单的:为什么要开处方?在“拿处方笺”之前,一个人必须能够清楚地表达出治疗的精确目标。我想用这种药达到什么目的?是否有替代疗法?在无法治愈的情况下,药物治疗是否有助于改善功能或生活质量?答案因具体情况而异。非甾体抗炎药由于其镇痛和抗炎的特性,在治疗许多牙齿和口腔面部疾病中是有用的。在TMD中,它们是治疗关节内急性(如胶囊炎)和慢性(如退行性关节疾病)炎症的首选药物[6,8,9]。非甾体抗炎药可以缓解肌痛的急性疼痛,但对慢性肌筋膜疼痛的治疗效果较差,这可能是因为大多数肌肉疼痛不是由炎症引起的[10]。所有非甾体抗炎药均抑制环氧合酶2 (COX-2),导致前列腺素E2合成减少,而前列腺素E2是炎症和疼痛致敏的关键介质[11]。不幸的是,大多数也阻断了结构相似的COX-1,这对血小板聚集、肾功能和胃肠道粘膜保护产生负面影响[12,13]。非甾体抗炎药在服用抗血小板和抗凝血药物的患者中要谨慎使用,因为出血风险增加,特别是在胃肠道中。消化道出血的危险因素包括既往消化道出血史、胃和十二指肠溃疡、幽门螺杆菌感染、饮酒和吸烟以及年龄超过65岁[13]。短期使用不太可能产生胃肠道症状,荟萃分析报告,当按推荐剂量服用非吲哚美辛非甾体抗炎药时,持续治疗2-3个月才会引起症状[14]。布洛芬被认为是颞下颌关节(TMJ)关节痛的一线治疗方法[15]。它有效、廉价且可广泛获得[8,15,16]。镇痛效果优于其他非甾体抗炎药[17];然而,需要更高的剂量(600 mg QID)才能产生与更有效的非甾体抗炎药相当的抗炎作用[18,19]。考虑到TMJ关节痛的疼痛缓解可能是由于炎症减少而不是直接疼痛缓解,抗炎作用是重要的考虑因素[20,21]。许多患者难以适应每天四次的剂量。每天服用一次药物可以帮助缓解这个问题。对于健康的人,我经常开始服用吡罗西康,每天10毫克,持续10 - 14天。虽然吡罗昔康是一种极好的抗炎药,但与许多非甾体抗炎药相比,它对胃肠道的副作用可能更大[16]。Cranio®:journal of craniomandibular & sleep practice 2020, vol . 38, no . 5。1,1 - 4 https://doi.org/10.1080/08869634.2020.1691707
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The first medications in my TMD toolbox
Temporomandibular disorders (TMDs) are a highly prevalent group of interrelated conditions affecting the temporomandibular joints, muscles of mastication, and intra-articular structures [1]. Understanding the pathophysiology of TMD and the nuances between subtypes is paramount in management, particularly when incorporating medications into care. Dentists expertly employ local anesthetics, analgesics, sedatives, and antibiotics in daily practice, but many feel less confident prescribing medications when treating TMD. This editorial will highlight medications I have found to be particularly useful, with an eye on optimal medication selection. In contrast to many musculoskeletal pain conditions, the great majority of individuals with TMD improve over time without invasive therapy [2–5]. While the effectiveness of conservative therapy is encouraging, this also suggests the potential role that medications may play to improve quality of life when symptoms are present. Unfortunately, pharmacotherapy in TMD has not been rigorously studied in large randomized trials [6,7]. When scientific literature is less than ideal, we are left to make the best choices for our patients with the data available. I encourage each of you to explore the data and compare my experiences with those in your practice to determine if judicious use of medication could be beneficial as part of a comprehensive care protocol. In my practice, I have found three classes to be particularly useful: non-steroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, and tricyclic antidepressants. Understanding the indications for each, and the characteristics of drugs in each class, allows for application in a variety of circumstances. The first consideration when prescribing is also the simplest: Why prescribe at all? Before “reaching for the prescription pad,” one must be able to clearly articulate the precise goals of therapy. What am I trying to accomplish with this drug? Are alternative therapies available? Would pharmacotherapy help to improve function or quality of life in a condition that cannot be cured? Answers vary in each individual circumstance. Non-steroidal anti-inflammatory drugs are useful in treating many dental and orofacial conditions, due to their analgesic and anti-inflammatory properties. In TMD, they are the drugs of choice in treating acute (e.g., capsulitis) and chronic (e.g., degenerative joint disease) inflammatory conditions within the joint [6,8,9]. NSAIDs can provide acute pain relief in myalgia but are less effective in treating chronic myofascial pain, likely because most muscular pain is not caused by inflammation [10]. All NSAIDs inhibit cyclooxygenase 2 (COX-2), resulting in decreased synthesis of prostaglandin E2, a key mediator in inflammation and pain sensitization [11]. Unfortunately, most also block structurally similar COX-1, which negatively affects platelet aggregation, kidney function, and protection of gastrointestinal mucosa [12,13]. NSAIDs are cautioned in patients taking antiplatelet and anticoagulant drugs, due to increased bleeding risk, especially in the GI tract. Risk factors for GI bleeding include past history of GI bleeding, gastric and duodenal ulcers, H. pylori infection, alcohol and tobacco use, and age over 65 [13]. Short-term use is unlikely to produce GI symptoms de novo, with meta-analysis reporting 2–3 months of continuous therapy to induce symptoms when non-indomethacin NSAIDs are taken at recommended doses [14]. Ibuprofen is considered first-line therapy in temporomandibular joint (TMJ) arthralgia [15]. It is effective, inexpensive, and widely available [8,15,16]. The analgesic effect compares favorably to other NSAIDs [17]; however, higher doses (600 mg QID) are required to produce anti-inflammatory effects comparable to more potent NSAIDs [18,19]. The anti-inflammatory effect is important to consider, given the observation that pain relief in TMJ arthralgia may be due to decreased inflammation rather than direct pain relief [20,21]. Many patients struggle to be compliant with fourtimes-daily dosing. Use of a once-daily medication can help alleviate this issue. In healthy individuals, I often begin with piroxicam 10 mg daily for 10–14 days. While it is an excellent anti-inflammatory, piroxicam has greater potential for GI side effects than many NSAIDs [16]. CRANIO®: THE JOURNAL OF CRANIOMANDIBULAR & SLEEP PRACTICE 2020, VOL. 38, NO. 1, 1–4 https://doi.org/10.1080/08869634.2020.1691707
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信